FDA Inspection 1032045 — Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd.
The FDA completed an inspection of Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd. on September 15, 2017 in Wuhan. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 15, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuhan (China)